U.S. advisory panel rolls back universal hepatitis B vaccine recommendation

The CDC's vaccine advisory panel has voted to discontinue the long-standing recommendation for administering the hepatitis B vaccine to newborns within 24 hours of birth, marking a significant shift in public health policy. This decision follows extensive debate and reflects changing perspectives on vaccination protocols for infants.

A key vaccine panel at the Centers for Disease Control and Prevention (CDC) voted 8-3 to discontinue the recommendation that all newborns receive a first dose of the hepatitis B vaccine. This decision marks a significant shift in public health policy, overturning decades of guidance that aimed to prevent infections and liver cancer in infants.

The CDC's vaccine advisory panel has rolled back its long-standing recommendation for all newborns to receive the hepatitis B vaccine, marking a significant shift in public health policy. This decision follows a series of contentious meetings characterized by misinformation and debate among panel members.

FDA Commissioner Marty Makary discussed the hepatitis B vaccine in an interview with NBC News, emphasizing the importance of rebuilding public trust in vaccination programs. He highlighted the vaccine's role in preventing serious health issues associated with hepatitis B.

A CDC advisory panel voted to discontinue the recommendation for the hepatitis B vaccine for all newborns, a decision that could limit access to this preventive measure for many families, particularly those in lower-income brackets.

A federal vaccine advisory committee is set to discuss the ongoing recommendation for newborns to receive the hepatitis B vaccine, which is recognized as the first vaccine capable of preventing cancer. This discussion comes amid scrutiny from officials associated with the Trump administration regarding vaccination policies.